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Abstract 
Inflammation is believed to play a role in prostate cancer (PCa) etiology, but it is unclear 
whether inflammatory markers C-reactive protein (CRP) and interleukin-6 (IL-6) associate with 
PCa risk in older men.  Using Cox regression, we assessed the relationship between baseline 
concentrations of CRP and IL-6 and subsequent PCa risk in the Cardiovascular Health Study, a 
population-based cohort study of mostly European American men ages >64 years (n=2234; mean 
follow-up = 8.7 years; 215 incident PCa cases).  We also tested associations between CRP and 
IL-6 tagSNPs and PCa risk, focusing on SNPs known to associate with circulating CRP and/or 
IL-6.  Results: Neither CRP nor IL-6 blood concentrations were associated with PCa risk.  The C 
allele of IL-6 SNP rs1800795 (-174), a known functional variant, was associated with increased 
risk in a dominant model (HR=1.44; 95% CI=1.03-2.01; p=0.03) but was not statistically 
significant after accounting for multiple tests (permutation p=0.21).  Our results suggest that 
circulating CRP and IL-6 do not influence PCa risk.  SNPs at the CRP locus are not associated 
with PCa risk in this cohort, while the association between rs1800795 and PCa risk warrants 
further investigation. 
 
Key Words: Prostate cancer, inflammation, C-reactive protein (CRP), interleukin-6 (IL-6), IL-6 
rs1800795 (-174)
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Introduction 
Inflammation may play a role in the etiology of prostate cancer (PCa) [1, 2].  Several 
surrogate measures of inflammatory status, such as history of prostatitis [3], history of sexually 
transmitted infections [4], and genetic variation in immune response genes [5], have been 
associated with PCa risk.  In addition, inflammation is often present in prostate biopsies, radical 
prostatectomy specimens, and tissues resected to treat benign prostatic hyperplasia [6].  Blood 
concentrations of inflammatory markers C-reactive protein (CRP), an acute phase protein 
produced by the liver, and interleukin 6 (IL-6), a cytokine and inducer of CRP, have been 
associated with poor prognosis and survival in PCa patients [7-11]. 
However, few prospective studies have examined the relationship between circulating 
markers of inflammation and subsequent PCa risk.  If blood concentrations of these markers 
associate with PCa risk, information on inflammatory markers could potentially be used to help 
identify individuals at high-risk for PCa and/or develop PCa prevention strategies.  Prospective 
data from the Rotterdam study, a cohort of individuals age >55 (242 PCa cases) [12], and CLUE 
II, a cohort of adults (18+ years) in Washington Country, MD (264 cases) [13] suggest that 
circulating CRP concentration is not associated with prostate cancer risk.  However, the 
relationship between CRP and PCa risk has not been evaluated in a cohort of men exclusively 
age 65 and older.  Because the prevalence of chronic inflammation increases with age [14], it is 
important to evaluate its effects in older populations.  The relationship between circulating IL-6 
and PCa risk has not been evaluated previously. 
In addition, several reports suggest that single nucleotide polymorphisms (SNPs) in or 
near CRP and IL-6 are associated with circulating concentrations of their respective protein 
products [15-19] and show functionality in vitro [15, 20, 21].  If these inflammatory markers are 
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causally involved in prostate carcinogenesis, then genetic variation within the CRP and IL-6 
gene regions may influence PCa risk and/or progression by altering gene regulation and protein 
expression.  Furthermore, such regulatory SNPs may be more reliable indicators of long-term 
blood concentrations than circulating biomarkers measured at a single time point due temporal 
variation in blood concentrations.  CRP or IL-6 SNPs could also influence PCa risk through 
alterations in protein structure and function. 
In order to determine if circulating concentrations of CRP or IL-6 influence PCa risk in 
older men, we tested associations between baseline measures of these markers and subsequent 
PCa using data from the Cardiovascular Health Study (CHS) [22].  To further investigate the 
relationships between these markers and PCa risk, we tested associations between CRP and IL-6 
tagSNP genotypes and PCa risk, focusing on SNPs previously shown to be associated with CRP 
and/or IL-6 blood concentrations in the CHS cohort [16, 18]. 
 
Materials and Methods 
Study Sample 
The Cardiovascular Health Study (CHS) is a population-based prospective, observational 
cohort study that was originally designed to investigate risk factors for coronary heart disease 
and stroke in the elderly (age 65 and older) [22].  Individuals were recruited from four 
communities in the U.S.: Sacramento County, CA; Forsyth County, NC; Pittsburgh, PA; and 
Washington County, MD [23].  A primarily European American (EA) cohort (n=5,201) was 
enrolled in 1989-1990, and an exclusively African American (AA) cohort (n=687) was enrolled 
in 1992-1993.  Medicare eligibility lists were used to identify potential participants, and 57.3% 
of eligible individuals were enrolled [23].   
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At baseline, a clinical examination was completed to collect both physical and self-
reported measures of potential risk factors for cardiovascular disease [23].  Phlebotomy was 
performed on the morning of the clinical exam after an 8–12 hour fast [24].  Anthropometric 
measures included height, weight, and waist and hip circumference.  Standard questionnaires 
were administered to obtain information on demographics, medical history, and health-related 
behaviors. Informed consent was obtained from all participants using methods approved by 
institutional review committees at each site [22].  All activities for the present study were 
approved by the University of Washington’s Human Subjects Review Committee. 
 
Outcomes 
CHS participants with a primary PCa diagnosis between 1989 and 2002 (n=215) were 
identified through record linkage with five population-based cancer registries serving the four 
CHS regions (described in [25]).  Cancer registry records were estimated to be 93–100% 
complete as measured by the standard of the North American Association of Central Cancer 
Registries [25].  Male participants were eligible for this analysis if they had donated a blood 
sample at baseline, provided informed consent for DNA analysis, and had no history of PCa at 
baseline according to either registry or baseline interview data. 
Registry data on stage and grade (collected using structured approaches) were used to 
classify tumors according to SEER summary stage and grade categories[26-28].  Tumors were 
classified as “local” (SEER summary stage 1, confined to prostate or clinically inapparent), 
“regional” (SEER summary stage 2-5: extension beyond the prostate capsule and/or regional 
lymph node involvement), or “distant” (SEER summary stage 7: distant site(s) and/or distant 
lymph nodes involved).  SEER grades 1 (well-differentiated), 2 (moderately differentiated), and 
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3 (poorly differentiated) correspond to Gleason scores of 2-4, 5-7, and 8-10 respectively.  In 
instances where cancers were recorded by two registries, stage categorizations were 100% 
concordant [27]. 
More aggressive PCa was defined as having either regional or distant stage or a Gleason 
score >8.  PCa was classified as less aggressive if the tumor stage was local and the Gleason 
score was <8.  If aggressiveness could not be determined due to missing data, aggressiveness 
was defined as “unknown”. 
 
Biological Measurements and Genotyping 
Samples were stored at -80°C for 5-6 years prior to CRP and IL6 measurement.  The 
number of freeze-thaw cycles was similar for each sample (2 to 3), and no significant changes in 
CRP have been observed over 5 freeze-thaw cycles [29].  CRP was measured in the entire cohort 
using stored plasma and a validated in-house high-sensitivity enzyme-linked immunosorbent 
assay (ELISA) [30] (coefficient of variation (CV): 6.2%) [31].  IL-6 was measured using stored 
serum and a commercial ELISA kit (Quantikine IL-6, R&D Systems, Minneapolis, MN, USA) 
(CV: 6.3%) [32].  The minimum detectable concentration for the IL-6 assay is reported to be, on 
average, 0.039 pg/ml (Quantikine HS human IL-6 Immunoassay).  All samples were run as one 
batch (same reagents used throughout) and in duplicate (resulting measures were averaged).  
Quality control samples were included on each plate (every 36 samples) to monitor differences 
between runs.  CVs were calculated as the overall means of the QC samples divided by the 
standard deviation.  IL-6 was measured successfully for fewer individuals than CRP due to 
insufficient serum volume, as the IL-6 assay has higher volume requirements. 
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SNPs with minor allele frequency (MAF) >0.05 were identified for both CRP [15, 16] 
and IL-6 [18] using sequence data obtained from 24 unrelated AA from the Coriell AA100 panel 
and 23 unrelated EAs from the Centre d’Etude du Polymorphisme Humain pedigrees as a part of 
the SeattleSNPs project (http://pga.mbt.washington.edu/).  Based on race-specific linkage 
disequilibrium (LD) and haplotype patterns across the CRP and IL-6 genes, four CRP tagSNPs 
(rs1417938, rs1800947, rs1205, rs2808630) and six IL-6 tagSNPs (rs1800796, rs1800795, 
rs2069837, rs1554606, rs2069849, rs1818879) were selected for genotyping in the EA samples 
[15, 16].  One additional CRP tagSNP (rs3093058) and three additional IL-6 tagSNPs 
(rs2069830, rs1474347, and rs1524107) were genotyped in AA samples in order to capture 
genetic variation common only in DNA of African ancestry.  SNPs were genotyped using 
TaqMan Assays-by-Design (Applied Biosystems, Foster City, CA) under standard conditions. 
Probe and primer sequences are available from the authors by request [16, 18]. 
 
Statistical Analysis 
Cox proportional hazards regressions were used to test the associations between 
circulating markers, genotypes, and PCa risk, as implemented in STATA (StataCorp. 2005. Stata 
Statistical Software: Release 9. College Station, TX: StataCorp LP).  Follow-up time was 
defined as the period between baseline interview and a first diagnosis of PCa, death, loss to 
follow-up, or the end of the study period (administrative censoring), whichever came first.  
Cancer registry data was available through different dates for the various registries, therefore 
administrative censor dates ranged from Dec. 1999 to Dec. 2004.  The average follow-up time 
was 8.9 years (range: 0.02-14.20 years) for participants enrolled in 1989-90, and 7.3 (range: 
0.01- 10.58 years) for participants enrolled in 1992-1993. 
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Individuals with CRP blood concentrations >10 mg/l were excluded from analyses of 
blood concentrations of inflammatory markers, due to the possibility that the elevated 
concentrations are the result of acute infection [33], but were included in analyses of tagSNP 
genotypes.  CRP and IL-6 blood concentrations were analyzed by quartiles and as natural log-
transformed values due to the skewness of their distributions (skewness was 1.48 before and 0.51 
after transformation of CRP; 4.5 before and 0.53 after transformation of IL-6).  Baseline CRP 
and IL-6 concentrations were tested for associations with PCa risk using two models. Model 1 
was adjusted for age (65-69, 70-74, 75-79, 80-84, and >85 years), race (EA and AA), and 
enrollment period (1989-90 and 1993-94), with race and enrollment period treated as strata 
variables within the Cox model.  Model 2 included additional variables that were associated with 
PCa risk in the CHS cohort at a conservative p<0.15 significance level in a multivariate Cox 
model, to control for confounding by potential PCa risk factors.  Candidate risk factors included, 
BMI (<25, 25-29.9, >30), diabetes status, smoking status, physical activity, study site/clinic, and 
current NSAID use.   Additional models were fit to investigate effect modification by BMI 
(above vs. below the median), and to test associations of CRP and IL-6 with more aggressive 
PCa (individuals with less aggressive PCa were censored at diagnosis date). 
To more stringently test the hypothesis that elevated CRP or IL-6 is a PCa risk factor, 
additional analyses of baseline CRP and IL-6 concentrations were conducted using only 
individuals free of cancer at year 5 of follow-up.  In other words, excluding individuals who 
developed cancer prior to year 5 reduced the probability that elevated CRP/IL-6 measurements 
were the consequence of undetected tumors, rather than a risk factor for tumor development. 
For each tagSNP, Hardy-Weinberg Equilibrium (HWE) was assessed independently for 
AAs and EAs, using the Pearson chi-square statistic.  Our primary hypothesis was that SNPs 
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known to be associated with circulating CRP and/or IL-6 concentrations in the CHS cohort 
would be associated with PCa risk.  Tests of other SNPs were exploratory in nature.  Previous 
CHS reports suggest that in EAs, circulating CRP is associated with CRP SNPs rs1417938 (also 
referred to as 1919), rs1800947 (2667), and rs1205 (3872); and IL-6 SNPs rs1800795 (1510), 
rs2069837 (2892), rs1554606 (3572), and rs1818879 (7592).  Associations with circulating IL-6 
have been reported for IL-6 SNPs rs1800795 (1510) and rs1554606 (3572).  In AA CHS 
participants, CRP SNPs rs3093058 (790) and rs1205 (3872) are associated with circulating CRP 
[16].  Associations for each SNP were tested in a multiplicative model (test of trend) and in 
dominant model (minor allele carriers vs. major allele homozygotes) using likelihood ratio tests, 
because their mode of inheritance with respect to circulating CRP and/or IL-6 is not always clear 
[16, 18].  Genotype analyses were adjusted for age and conducted separately for EAs and AAs.  
Hazard Ratios (HRs) for a codominant model are also presented to aid in the interpretation of our 
formal tests of significance.  For SNPs associated with PCa risk, the proportional hazards 
assumption was tested on the basis of Schoenfeld residuals using the stphtest function in 
STATA. 
 To consider the consequences of multiple testing on our SNP analyses, we calculated 
permutation-based p-values using an in-house program written in STATA.  For the seven SNPs 
that associated with either CRP or IL-6 concentrations in the CHS cohort, we randomly matched 
the genotype data (preserving LD structure) to the phenotype data for all 2,015 EA individuals, 
1,000 times, generating 1,000 datasets.  Each dataset was analyzed under multiplicative and 
dominant models, resulting in 14 likelihood ratio test p-values for each permutation.  The lowest 
p-value from each permuted analysis was used to construct a null distribution of minimal p-
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values.  This distribution was used to calculate a ‘permuted p-value’ for our lowest nominal p-
value. 
 
Results 
Characteristics of the cohort are presented in Table 1.  Of the 2,277 men that provided 
blood and consented to DNA analysis, 43 were diagnosed with PCa prior to baseline and were 
ineligible (Figure 1).  Among the 2,234 participants eligible for analysis, there were 215 cases of 
incident PCa identified, during an average of 8.7 years of follow-up per person.  At baseline, the 
mean age was 73.3 years, the mean BMI was 26.4 kg/m², and the percentage of current smokers 
was 10.8 %.  For men with CRP <10 mg/l, mean CRP was 2.61 ± 2.02 mg/l and mean IL-6 was 
2.13 ± 1.61 mg/l.  When compared to EAs, AA participants had a higher mean CRP 
concentration, lower mean physical activity, and a higher prevalence of current smoking. 
 
CRP and IL-6 blood concentrations and PCa risk 
Of the eligible study participants, 2,214 and 2,023 individuals had measures for CRP (20 
missing) and IL-6 (211 missing) blood concentrations, respectively (Table 1 and Figure 1).  Of 
the individuals with CRP measurements, 229 had CRP >10 mg/l, suggesting acute infection.  
These individuals were excluded from primary analyses of CRP and IL-6 blood concentrations.  
Race, diabetes, age, NSAID use, and study site/clinic were determined to be independent 
predictors of PCa at the p=0.15 level, and each remained significant in a multivariate model.   
These variables were retained as potential confounders in all analyses of circulating CRP and IL-
6. 
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Significant associations with PCa risk were observed for neither CRP nor IL-6, after 
adjustment for potential confounding factors (Table 2).  Similar results were observed in 
analyses unadjusted for potential confounders (data not shown).  HRs for CRP and IL-6 were 
similar by quartile.  For both CRP and IL-6, a slight non-significant increase in risk was 
observed for the second and third quartiles, but no increase in risk was observed for the highest 
quartile.  Similar associations were observed when CRP was analyzed using the American Heart 
Association’s CRP categories (<1, 1-3, and >3 mg/l) [33], with elevated risk for the 1-3 mg/l 
category (HR=1.36; 95% CI=0.95-1.96) and no excess risk for the >3 mg/l category (HR=0.97; 
95% CI=0.64-1.48).  Results were similar when the analysis was repeated including participants 
with CRP >10mg/l (data not shown) and excluding men diagnosed with PCa within 5 years of 
enrollment (Table 2).  When aggressive PCa was defined as the outcome (n=74), neither CRP 
nor IL-6 blood concentration was associated with PCa risk (test of trend p=0.84 and p=0.65, 
respectively).  Further, no significant associations were observed when the data were analyzed 
stratified by race or the median BMI, or when a CRP-IL-6 interaction term was tested (data not 
shown).  
 
CRP/IL-6 genotypes and PCa risk 
For the CRP SNPs, no statistically significant deviations from HWE were detected in 
AAs or EAs.  For the IL-6 SNPs, rs2069837 (2892) showed a significant deviation from HWE in 
EAs only (p=0.02), primarily due to an excess of rare homozygotes.   
Associations between all SNP genotypes and PCa risk are shown in Table 3, with SNPs 
of putative functional significance shown in bold.  No CRP SNPs showed significant association 
with PCa risk in EAs or AAs.  In EAs, increased risk of PCa was associated with the C allele of 
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IL-6 functional SNP rs1800795 (1510) when treated as the dominant allele (C carrier vs. TT 
HR=1.44; 95% CI=1.03-2.01; p=0.03).  Increased risk was also observed for the C allele when it 
was tested as a dominant allele (LRT p=0.029; permutation-p=0.21).  The magnitude of this 
association was stronger in the more aggressive PCa cases (C carrier vs. TT HR=1.79; 95% 
CI=0.98-3.27) than in the less aggressive cases (C carrier vs. TT HR=1.10; 95% CI=0.65-1.85).  
The proportional hazards assumption was not violated for either rs1800795, as indicated by 
Schoenfeld residuals.   
 
Discussion 
In this population-based cohort of men age 65 and older, pre-diagnostic blood 
concentrations of neither CRP nor IL-6 appear to be associated with subsequent PCa risk overall, 
or with risk of a PCa with an aggressive phenotype.  The C allele at IL-6 SNP rs1800795 (MAF 
= 0.41), a functional polymorphism located in the IL-6 promoter region, was associated with an 
increase in PCa risk (nominal p=0.03), but the permutation p-value (p=0.21) suggests that this 
finding may be a consequence of multiple testing.   
Previous reports suggest that SNPs in the IL-6 promoter region, including rs1800795 
(also known as IL-6 -174), are functional, influencing expression levels in HeLa cell lines [20, 
21].  However, results from functional studies of rs1800795 are inconsistent: Fishman et al. and 
Terry et al. report increased IL6 transcription in HeLa cells for the G allele and the C allele, 
respectively, while Terry et al. demonstrates that regulation of IL6 transcription is cell specific.  
Observational studies in humans suggest that the C allele of rs1800795 is associated with 
elevated circulating IL-6 concentrations [34, 35] with some inconsistency [20].  These 
inconsistencies do not appear to be due to confusion related to the palindromic nature of this 
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SNP.  CHS investigators report that the C allele of rs1800795 is associated with elevated 
concentrations of circulating CRP (p=0.0008) and IL-6 (0.04) in the CHS cohort [18], suggesting 
that rs1800795, or a SNP in LD with rs1800795, may influence PCa risk through regulation of 
IL-6 RNA and subsequent protein expression.  However, the lack of an association between 
circulating IL-6 concentration and PCa risk indicates that rs1800795 may influence PCa risk 
through an alternate mechanism, or that the true association between IL-6 and PCa risk has been 
masked by (1) an unmeasured confounder, (2) the instability of IL-6 in serum, or (3) the 
inadequacy of a single measurement of IL-6 as an indicator of long-term blood concentration.  It 
is also possible that the association between rs1800795 and PCa risk is a false positive, as 
suggested by the p-value obtained via permutation (p=0.21).  According to the SeattleSNPs 
Genome Variation Server (http://gvs.gs.washington.edu/GVS/), SNPs in strong LD (r2>0.8) with 
rs1800795 in EAs include rs1474347, rs1474348, rs1554606, rs1800797, rs2069832, rs2069833, 
and rs2069845, all non-coding variants. 
Few studies have assessed the relationships between IL-6 or CRP SNPs and PCa risk.  A 
large Swedish case-control study found no association between any of six IL-6 tagSNPs and PCa 
risk, although a non-significant association with increasing PCa risk (OR=1.18; 95% CI=0.91-
1.52) was observed for the CC genotype of rs1800795, consistent with the results of this work 
[36].  In a small study of 95 PCa patients, the C allele at rs1800795 was associated with 
aggressiveness and recurrence of PCa [37].  For CRP, results from the Rotterdam Study suggest 
that common variation within the CRP gene is not associated with PCa risk [12], consistent with 
our results. 
This study also suggests that there is no clear relationship between circulating 
concentrations of CRP or IL-6 and PCa risk, consistent with prospective data on CRP from the 
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Rotterdam Study [12] and the CLUE II Study [13].  Ours is the first study to evaluate the 
association between circulating IL-6 and PCa risk, and no association was observed. 
Because the present analysis considers the potential effects of both genotypes and blood 
concentrations of CRP and IL6, it provides a comprehensive picture of the relationships between 
PCa and these inflammatory markers.  The use of pre-diagnostic measures of circulating 
biomarkers in a prospective study design minimizes the potential for reverse causality, and 
selection of tagSNPs insures that all common variation (MAF >5%) in the CRP gene region is 
tested.  The complete ascertainment of PCa cases in this cohort reduces the potential for selection 
bias. 
This work is limited by the lack of data on PCa screening and family history of PCa, two 
factors known to increase the probability of being diagnosed with PCa [38, 39].  If either of these 
factors is associated with CRP/IL6 concentrations or genotypes, the magnitude of the 
associations reported may be biased due to confounding.  In addition, only 215 incident cases of 
PCa were observed in this cohort, limiting power to detect modest associations, especially in 
analyses of AAs only (40 PCa cases) and in analyses of the aggressive prostate cancer phenotype 
(74 PCa cases).  For example, the minimum detectable allelic HR for CRP SNP rs3093058 (790), 
a functional SNP [15] present in AAs only, is 2.4, based on a multiplicative model.  This study 
was also underpowered to detect statistical interactions between circulating biomarkers and SNP 
genotypes.  Finally, this study investigates the role of only two biomarkers in the complex 
inflammation pathway, providing a limited view of the role of inflammation in PCa risk. 
In conclusion, we found no relationship between PCa risk and blood concentrations of 
either CRP or IL-6.  The results presented here are consistent with previous studies and suggest 
that circulating levels of CRP and IL-6 are not associated with PCa risk.  Genetic variation 
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within CRP does not appear to influence PCa risk in this cohort, while the association between 
IL-6 rs1800795 and PCa risk warrants further investigation. 
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Figure 1.  Description of the Cardiovascular Health Study participants eligible for analyses.  
PCa, prostate cancer; CRP, C-reactive protein; IL-6, interleukin-6; EA, European American; AA, 
African American 
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Table 1.  Characteristics of eligible participants from the Cardiovascular Health Study.  
Values are shown as frequencies and (%) unless otherwise indicated 
 Total European 
Americans 
African 
Americans 
N 2,234 1,934 300 
Mean follow-up  per person, years 8.7 8.9 7.3 
Number of incident PCa cases 215 (9.6) 175 (9.1) 40 (13.3) 
    
Age in years at baseline, mean ± 
SD 
73.3 ± 5.7 73.4 ± 5.7 72.7 ± 5.8 
     65-69 684 (30.6) 579 (29.9) 105 (35.0) 
     70-74 748 (33.5) 640 (33.1) 108 (36.0) 
     75-79 449 (20.1) 403 (20.8) 46 (15.3) 
     80-84 251 (11.2) 225 (11.6) 26 (8.7) 
     >85 102 (4.6) 87 (4.5) 15 (5.0) 
    
BMI (kg/m²), mean ± SD 26.4 ± 3.8 26.4 ± 3.7 26.6 ± 4.3 
     <25.0 808 (36.2) 703 (36.4) 105 (35.0) 
     25.0-29.9 1,077 (48.2) 937 (48.5) 140 (46.7) 
     >30.0 341 (15.3) 287 (14.8) 54 (18.0) 
     Missing 8 (0.4) 7 (0.4) 1 (0.3) 
    
Clinic    
     NC (Bowman Gray) 541 (24.2) 445 (23.0) 96 (32.0) 
     CA (Davis) 584 (26.1) 495 (25.6) 89 (29.7) 
     MD (Hopkins) 530 (23.7) 526 (27.2) 4 (1.3) 
     PA (Pittsburg) 579 (25.9) 468 (24.2) 111 (37.0) 
    
Smoking    
     Never 716 (32.1) 619 (32.0) 97 (32.3) 
     Former 1,273 (57.0) 1,131 (58.5) 142 (47.3) 
     Current 242 (10.8) 182 (9.4) 60 (20.0) 
     Missing 3 (0.1) 2 (0.1) 1 (0.3) 
    
Physical activity, kcal/mo  481 ± 534 508 ± 550 312 ± 372 
    Median (IQR) 309 (119-663) 330 (132-703) 197 (67-423) 
    
Diabetes 753 (33.7) 645 (33.4) 108 (36.0) 
     Missing 11 (0.5) 1 (0.1) 10 (3.3) 
    
Current NSAID use 220 (9.9) 188 (9.7) 32 (10.7) 
    
Alcohol, beverages/week 3.8 ± 8.3 3.9 ± 8.1 3.4 ± 9.0 
     Median (IQR) 0.25 (0.0-3.0) 0.25(0.0-3.0) 0.0 (0.0-2.0) 
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 Total European 
Americans 
African 
Americans 
    
CRP blood concentration (mg/l)1    
     Median (IQR) 2.4 (1.2-4.2) 2.3 (1.2-4.1) 3.0 (1.5-5.2) 
     Mean ± SE 4.7 ± 8.8 4.6 ± 9.1  5.1 ± 6.8 
     Range 0.1-142.6 0.1-142.6 0.2-61.3 
     ln(CRP), mean ± SE 0.9 ± 1.1 0.9 ± 1.0 1.1 ± 1.0 
     Missing 20 (0.9) 14 (0.7) 6 (2.0) 
     CRP >10 mg/l 229 (11.2) 186 (10.3) 43 (16.3) 
    
IL-6 blood concentration (pg/ml)2    
     Median (IQR) 1.8 (1.3-2.7) 1.8 (1.3-2.7) 1.7 (1.2-2.8) 
     Mean ± SE 2.3 ± 1.9 2.4 ± 1.9 2.2 ± 1.6 
     Range 0.3-23.6 0.3-23.6 0.4-12.1 
     ln (IL6), mean ± SE 0.7 ± 0.6 0.7 ± 0.6 0.6 ± 0.6 
     Missing 211 (9.4) 184 (9.5) 27 (9.0) 
    
Stage of disease    
     Local 114 (53.0) 88 (50.3) 26 (65.0) 
     Regional 26 (12.1) 20 (11.4) 6 (15.0) 
     Distant 11 (5.1) 10 (5.7) 1 (2.5) 
     Unknown 64 (29.8) 57 (32.6) 7 (17.5) 
    
Gleason score    
     2-4 31 (14.4) 25 (14.3) 6 (15.0) 
     5-7 113 (52.6) 89 (50.9) 24 (60.0) 
     8-10 49 (22.8) 39 (22.3) 10 (25.0) 
     Unknown 22 (10.2) 22 (12.6) 0 (0.0) 
1 Based on a total sample size of 2,214 (20 missing) 
2 Based on a total sample size of 2,023 (211 missing)
25 
 
Table 2.  Hazard ratios (HR) and 95% confidence intervals (95% CI) for associations 
between baseline C-reactive protein and interleukin-6 concentrations (by quartiles) and 
prostate cancer risk1 
 No. Cases/ 
cohort 
Total 
Person-
Years 
HR2 95% CI2 
CRP (mg/l)     
     <1.10 46 4673 1.00 Ref 
     1.10-2.11 59 4572 1.27 0.86-1.87 
     2.11-3.47 55 4332 1.29 0.87-1.91 
     >3.47 42 4024 1.03 0.67-1.57 
     Log(CRP)   1.02 0.85-1.21 
     
IL-6 (mg/l)     
     <1.23 51 4668 1.00 Ref 
     1.23-1.69 57 4256 1.24 0.84-1.83 
     1.69-2.47 45 3800 1.17 0.78-1.76 
     >2.47 32 3624 0.90 0.57-1.40 
     Log(IL-6)   0.97 0.74-1.27 
     
Excluding cases diagnosed in first 5 years 
CRP (mg/l)     
     <1.10 17 4107 1.00 Ref 
     1.10-2.11 25 4188 1.38 0.74-2.56 
     2.11-3.47 18 4099 0.98 0.50-1.92 
     >3.47 17 3975 1.06 0.54-2.10 
     Log(CRP)   1.01 0.76-1.36 
     
IL-6 (mg/l)     
     <1.23 19 4010 1.00 Ref 
     1.23-1.69 28 3862 1.61 0.89-2.90 
     1.69-2.47 14 3726 0.83 0.41-1.70 
     >2.47 14 3597 0.98 0.48-1.98 
     Log(IL-6)   0.84 0.54-1.29 
1 Excluding individuals with baseline CRP >10 mg/l 
2 Adjusted for age, race, enrollment period, diabetes status, current NSAID use, and clinic
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Table 3. Associations1 between C-reactive protein and interleukin-6 tagSNPs and prostate 
cancer risk by race, adjusted for age, enrollment period, and clinic. 
 EAs (n=2,015)  AAs (n=311) 
SNP2 (position3) Cases/Cohort HR 95% CI  Cases/Cohort HR 95% CI 
        
CRP SNPs        
rs3093058 (790)        
AT or TT --    14/94 1.15 0.60-2.22 
AA --    26/206 1.00 Ref 
AT --    12/85 1.09 0.55-2.18 
TT --    2/9 1.74 0.40-7.49 
     Ptrend=0.56   
rs1417938 (1919)        
AT or TT 92/1013 1.02 0.75-1.36  9/70 0.88 0.42-1.85 
AA 83/921 1.00 Ref  31/230 1.00 Ref 
AT 69/830 0.92 0.67-1.27  8/66 0.84 0.39-1.83 
TT 23/183 1.38 0.87-2.20  1/4 1.40 0.18-10.98 
 Ptrend=0.45    Ptrend=0.83   
rs1800947 (2667)        
GC or CC 22/242 1.05 0.67-1.64  2/11 1.10 0.26-4.69 
GG 153/1691 1.00 Ref  38/289 1.00 Ref 
GC 21/236 1.02 0.65-1.62  2/11 1.10 0.26-4.69 
CC 1/6 1.98 0.28-14.21  0/0 -- -- 
Missing 1    0   
 Ptrend=0.76    Ptrend=0.90   
rs1205 (3872)        
GA or AA 90/1062 0.89 0.66-1.20  13/102 0.99 0.51-1.94 
GG 85/871 1.00 Ref  27/198 1.00 Ref 
GA 72/845 0.91 0.67-1.25  11/94 0.90 0.44-1.82 
AA 18/217 0.83 0.50-1.38  2/8 2.44 0.56-10.58 
Missing 1    0   
 Ptrend=0.41    Ptrend=0.74   
rs2808630 (5237)        
AG or GG 86/908 1.08 0.80-1.46  16/116 1.03 0.54-1.96 
AA 89/1026 1.00 Ref  24/184  1.00 Ref 
AG 73/760 1.10 0.81-1.51  16/107 1.12 0.59-2.15 
GG 13/148 0.98 0.54-1.75  0/9 0.00 -- 
 Ptrend=0.76    Ptrend=0.75   
        
IL-6 SNPs        
rs1800796 (1111)        
GC or CC 19/194 1.07 0.66-1.72  3/47 0.36 0.11-1.19 
GG 156/1740 1.00 Ref  37/253 1.00 Ref 
GC 19/192 1.08 0.67-1.74  2/46 0.25 0.06-1.05 
CC 0/2 0.0 --  1/1 3.47 0.39-30.96 
 Ptrend=0.83    Ptrend=0.14   
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 EAs (n=2,015)  AAs (n=311) 
SNP2 (position3) Cases/Cohort HR 95% CI  Cases/Cohort HR 95% CI 
        
rs1800795 (1510)        
GC or CC 127/1237 1.44 1.03-2.01  6/50 0.91 0.38-2.17 
GG 48/696 1.00 Ref  34/250 1.00 Ref 
GC 96/901 1.49 1.05-2.11  5/48 0.79 0.31-2.02 
CC 31/336 1.30 0.82-2.04  1/2 4.14 0.53-32.68 
Missing 1    0   
 Ptrend=0.14    Ptrend=0.92   
rs2069830 (2002)        
CT or TT --    8/31 1.52 0.96-3.31 
CC --    32/259 1.00 Ref 
CT --    7/38 1.44 0.63-3.28 
TT --    1/3 2.51 0.30-20.65 
     Ptrend=0.27   
rs2069837 (2892)        
AG or GG 29/319 1.04 0.70-1.56  10/53 1.70 0.82-3.50 
AA 146/1613 1.00 Ref  30/247 1.00 Ref 
AG 24/295 0.93 0.60-1.44  10/52 1.69 0.82-3.50 
GG 5/24 2.46 1.00-6.06  0/1 0.67 0.00-- 
Missing 2    0   
 Ptrend=0.48    Ptrend=0.17   
rs1474347 (2989)        
AC or CC     13/93 1.04 0.53-2.03  
AA --    27/207 1.00 Ref 
AC --    10/81 0.90 0.43-1.88 
CC --    3/12 2.05 0.60-7.00 
     Ptrend=0.61   
rs1524107 (3084)        
CT or TT     2/33 0.36 0.08-1.51 
CC --    38/267 1.00 Ref 
CT --    2/33 0.36 0.08-1.51 
TT --    0/0 -- -- 
     Ptrend=0.10   
rs1554606 (3572)        
GT or TT 128/1301 1.25 0.90-1.76  20/161 0.82 0.44-1.54 
GG 47/623 1.00 Ref  20/138 1.00 Ref 
GT 93/926 1.29 0.90-1.83  15/121 0.81 0.41-1.60 
TT 35/375 1.16 0.76-1.83  5/40 0.84 0.31-2.26 
Missing 10    1   
 Ptrend=0.38    Ptrend=0.60   
rs2069849 (6021)        
CT or TT 5/109 0.45 0.19-1.11  9/73 0.86 0.40-1.86 
CC 170/1825 1.00 Ref  31/227 1.00 Ref 
CT 5/108 0.46 0.19-1.11  8/69 0.81 0.37-1.81 
TT 0/1 -- --  1/4 1.67 0.21-12.98 
 Ptrend=0.05    Ptrend=0.84   
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 EAs (n=2,015)  AAs (n=311) 
SNP2 (position3) Cases/Cohort HR 95% CI  Cases/Cohort HR 95% CI 
        
rs1818879 (7592)        
GA or AA 84/990 0.88 0.65-1.19  11/103 0.64 0.32-1.30 
GG 91/944 1.00 Ref  29/197 1.00 Ref 
GA 70/804 0.91 0.66-1.24  11/95 0.71 0.35-1.44 
AA 14/186 0.78 0.44-1.37  0/8 -- -- 
 Ptrend=0.33    Ptrend=0.13   
1P-values are not adjusted for multiple tests. 
2SNPs associated with CRP and/or IL-6 blood concentrations in the CHS cohort are in bold and 
underlined. 
3The CRP and IL-6 SNP positions are relative to GenBank accession numbers AF449713 and 
AF372214, respectively. 

